Actively Recruiting
GR1803 Injection in Patients With RRMM
Led by Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Updated on 2025-04-30
30
Participants Needed
1
Research Sites
135 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.
CONDITIONS
Official Title
GR1803 Injection in Patients With RRMM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ECOG performance status score between 0 and 2
- 18 years of age or older
- Diagnosis of multiple myeloma complicated by extramedullary plasmacytoma
You will not qualify if you...
- Prior treatment with any BCMA-targeted therapy
- Active central nervous system involvement or clinical signs of meningeal involvement of multiple myeloma
- Known allergies, hypersensitivity, or intolerance to the study drug (teclistamab) or its excipients
- Diagnosis of plasma cell leukemia, Waldenstr�f6m's macroglobulinemia, POEMS syndrome, or primary amyloid light-chain amyloidosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 250033
Actively Recruiting
Research Team
G
Gang An, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here